Pan American Journal of Public Health: Recently published articles / NEW info on COVID-19 for authors and readers

Clinical trials of drug repositioning for COVID-19 treatment 

Sandro Rosa and Wilson Santos

Brief communication l Published March 20 2020 l https://doi.org/10.26633/RP

Pan American Journal of Public Health: Recently published articles / NEW info on COVID-19 for authors and readers

No evidence supports the use of ether and chloroform inhalation for treating COVID-19 

Paulo Ricardo Martins-Filho and Victor Santana Santos

Letter to the editor l Published March 24 2020 l https://doi.org/10.26633/RPSP.2020.41

• FDA added hydroxyclhloroquine sulfate to category I under the interim policy on compounding bulk substances. Documents available at: https://www.fda.gov/media/94164/download

https://www.fda.gov/media/94402/download

• FDA published instructions to facilitate the entry of needed products including personal protective equipment. Information on products that can be imported into the USA wihout engaging the FDA has been provided to importers and manufacturers. Documents are available at https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-takes-action-increase-us-supplies-through-instructions-ppe-and

• The Emergency Use Authorizations by the FDA for diagnostic tests are available at : https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization

This document provides interim guidance on the management of the blood supply in response to the pandemic outbreak of coronavirus disease (COVID-19). It is intended for blood services, national health authorities, and others responsible for the provision of blood and blood components and integration of the blood system within the public health system. WHO will continue to update this guidance as new information becomes available.

Please, go to https://apps.who.int/iris/rest/bitstreams/1272656/retrieve

REFERENCE NUMBERS

PAHO’s Regional Program on Bioethics has developed a document that provides ethics guidance for the public health response, health care delivery and research during current COVID-19 pandemic.

Such document is available at: https://www.paho.org/en/documents/ethics-guidance-issues-raised-novel-coronavirus-disease-covid-19-pandemic.

In the virtual seminar to PAHO’s ethics guidance for COVID-19 research was presented the imperatives to conduct rapid ethics review of COVID-19 research protocols and to promote future research through the use of broad consent were discussed.  The recording is available at: https://paho.webex.com/recordingservice/sites/paho/recording/718eb53feb6b4ba1abe8529be1b96586

Investigational COVID-19 Convalescent Plasma – Emergency INDs

FDA is facilitating access to COVID-19 convalescent plasma for use in patients with serious or immediately life-threatening COVID-19 infections through the process of single patient emergency Investigational New Drug Applications (eINDs) for Individual patients under 21 CFR 312.310. This process allows the use of an investigational drug for the treatment of an individual patient by a licensed physician upon FDA authorization. This does not include the use of COVID-19 convalescent plasma for the prevention of infection.

Click here to access the complete information.

http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/dr-reddys-laboratories-issues-voluntary-nationwide-recall-phytonadione-injectable-emulsion-usp-10